Thyroid DiseasesNCT04794257
NerveTrend vs. i-IONM in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.
A study testing Neuromonitoring of the recurrent laryngeal nerves in people with Thyroid Diseases and Surgery, run by Marcin Barczynski at 1 site in Poland.
Trial summary
The aim of this study is to compare two distinct modes of NIM Vital application in thyroid surgery: i-IONM vs. NerveTrend mode with respect to prevalence of early postoperative RLN injury. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Thyroid Diseases, Surgery, Recurrent Laryngeal Nerve Injuries
- What is being tested?
- Neuromonitoring of the recurrent laryngeal nerves
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 264 participants
- Where
- 1 sitePoland
- Study dates
- 1 Apr 2021to 31 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- planned, first-time, bilateral thyroid surgery.
Who cannot join
- planned unilateral thyroid surgery,
- previous thyroid surgery,
- pregnancy
- lactation
- age < 18 years
- age > 65 years
- ASA 4-5 grade (American Society of Anesthesiology)
- inability to comply with the follow-up protocol
Trial locations and contacts
1 site in 1 country.
Poland1 site, 1 recruiting
- Recruiting
Department of Endocrine Surgery, Jagiellonian University College of Medicine
Krakow, 31-202
Marcin Barczynski, MD, PhD, +48602375939, marbar@mp.pl
Marcin Barczynski, MD, PhD
About this study
Official title: Clinical Validation of NerveTrend vs. Conventional i-IONM Mode of NIM Vital in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.
The aim of this study is to compare two distinct modes of NIM Vital application in thyroid surgery: i-IONM vs. NerveTrend mode with respect to prevalence of early postoperative RLN injury.
The hypothesis explored in this study is that NerveTrend mode may be more accurate than conventional i-IONM mode in intraoperative identification of impending neural injury and in prognostication of postoperative glottis function in monitored bilateral thyroid surgery. Hence, NerveTrend mode may be considered a bridge between i-IONM and c-IONM modes, and particularly in health care environments with limited financial resources it can be considered a substantial step forward representing a modern alternative to the c-IONM technique and providing benefits over conventional i-IONM mode.
Read more
A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each).
The primary outcome measure is prevalence of recurrent laryngeal nerve (RLN) injury (%) on postoperative day 1 assessed by direct laryngoscopy.
Read the detailed description
Over the past two decades, intraoperative neural monitoring (IONM) has evolved into a mature risk minimization tool. Meta-analyses of studies, most of which were limited by poor study designs and the sole use of intermittent nerve stimulation, failed to clearly demonstrate superiority of intermittent IONM (i-IONM) over anatomic visual recurrent laryngeal nerve (RLN) dissection in the absence of IONM. However, a substantial number of systematic reviews of i-IONM in thyroidectomy have conflicting results, but their mean methodological quality is critically low. Sanabria et al suggested that design of a systematic review should comply with methodological standards and recommendations to offer relevant and practical information for decision making. In particular, with the advent of continuous IONM (c-IONM), intraoperative nerve electromyographic tracings, registered almost in real time during the operation, accurately predict postoperative vocal fold function when International Neural Monitoring Study Group (INMSG) quality standards are adhered to. Despite promising data on benefits of c-IONM is still remains rarely utilized worldwide in thyroid surgery. C-IONM aids in avoiding permanent traction-related nerve injury by urging surgeons to reverse harmful surgical maneuvers. C-IONM also forms an integral part in the surgical concept of staged thyroidectomy. Delaying completion surgery on the other side until nerve function has recovered practically abolishes the risk of bilateral vocal fold palsy. C-IONM has greatly furthered our understanding of functional RLN injury, enabling conception of effective risk minimization strategies tailored to the individual patient. As recently reported by Schneider at al c-IONM is superior to i-IONM in preventing vocal cord palsy. Based on nerves at risk (5208 versus 5024 nerves), c-IONM had in this study a 1.7-fold lower early postoperative vocal cord palsy rate than i-IONM (1.5 versus 2.5 %). This translated into a 30-fold lower permanent vocal cord palsy rate (0.02 versus 0.6 %). Early postoperative vocal cord palsies were 17.9-fold less likely to become permanent with c-IONM than i-IONM.
On the other hand, a brand new NIM Vital equipment allows now for using i-IONM in quasi continuous mode which is termed NerveTrend mode. This concept is a natural evolution of i-IONM towards c-IONM mode but is operator dependent and not automatic as in c-IONM mode. Hence, careful clinical validation of NerveTrend mode is needed in order to identify its clinical pertinence with respect to preventing neural damage compared to the standard of i-IONM mode in thyroid surgery. A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each).
Patients who will sign the informed consent will be randomized to two groups: i-IONM vs. NerveTrend application during planned total thyroidectomy.
The standardized approach to IONM will be used as outlined by the guidelines of the International Neural Monitoring Study Group in Thyroid and Parathyroid Surgery.
All the operations will be performed under general anesthesia by two experienced endocrine surgeons (MB, AK) with annual volume of thyroid surgery > 300 cases, each. The anesthesia protocol is: intravenous midazolam premedication, induction with fentanyl, thiopental and suxamethonium, endotracheal intubation and sevoflurane maintenance. No other muscle relaxants are used during surgery. A standard cervicotomy is used in all the patients. Visual identification of RLN low in the neck (below the crossing with the inferior thyroid artery) will facilitated by the use of the IONM system employing the nerve mapping technique. Once the nerve iss visually identified, repeated stimulations with the IONM monopolar probe served to trace the nerve path in the operative field and test its functional integrity during dissection. In each patient, RLN will be exposed and the branches of the superior and inferior thyroid arteries will be divided close to the thyroid capsule.
NIM Vital (Medtronic, Jacksonville, US) will be used. The NIM Vital system operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid ("laryngeal twitch"). In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
LOS is defined as absence of EMG signal following stimulation of the ipsilateral vagus nerve, EMG signal amplitude below 100 μV following stimulation with 1-2 mA current in dry field, lack of palpable "laryngeal twitch" or visible laryngeal movement following stimulation of the ipsilateral vagus nerve. To differentiate between true and false LOS, the INMSG-proposed problem-solving algorithm will be employed intraoperatively. In cases intraoperatively recognized as true LOS, the neuromapping technique is used to determine the character of nerve damage (segmental- type I, global - type II), and the localization of the injury site.
IONM assessment is based on the definition by Chan and Lo. The percentage of RLN dysfunctions is calculated per the number of RLNs at risk and not per the number of patients. Loss of signal after vagal stimulation following thyroid lobe resection (V2) is classified as a positive test result prognosticating ipsilateral vocal cord paresis. The test is interpreted as true positive (TP) when laryngoscopy confirmed ipsilateral vocal cord paresis, and false positive (FP) when the mobility of the ipsilateral vocal fold is normal. Preserved normal signal following vagal stimulation after thyroid lobe resection (V2) is classified as a negative result that prognosticated normal postoperative mobility of the ipsilateral vocal fold. The test is interpreted as true negative (TN) when laryngoscopy demonstrated postoperative normal mobility of the ipsilateral vocal fold and as false negative (FN) when ipsilateral vocal fold paresis is seen postoperatively.
Power calculation for the study: The sample size is estimated based on the principle of detecting a 5% difference in the prevalence of early RLN injury (6% for i-IONM vs. 1% for NerveTrend) with a 80% probability at p < 0.05. Assuming a 20% drop out rate a group of 528 nerves at risk (assessed in 264 patients undergoing bilateral thyroid surgery) should be enough to test if clinically pertinent differences exist between i-IONM vs. NerveTrend modes (n = 264 nerves at risk which is equal to 132 patients in each respective group undergoing bilateral thyroid surgery). The resultant data will be statistically processed using the statistical software MedCalc (version 19, MedCalc Software, Belgium). Assessment of the changeability of the investigated parameters will be presented by arithmetic means, median values, standard deviations (SD), minimum and maximum values (min - max), 95% confidence interval (95% CI) and percentage of prevalence (%). An inter-group comparison of particular properties will be done by means of the Chi-2 test (non-parametric variables) and by the univariate analysis of variance ANOVA (parametric variables). To assess the diagnostic accuracy of intraoperative neuromonitoring, the Receiver Operating Characteristics (ROC) curves will be analyzed and the Area Under Curve (AUC) values will be compared based on the non-parametric method of DeLong et al.
Thus, the predictive values of the positive and negative results will be calculated and the most optimal predictive criterion will be identified for i-IONM vs NerveTrend, separately. The incidence of nerve events will be calculated based on the number of nerves at risk. The significance level is accepted at p < 0.05.
- Being tested
- Neuromonitoring of the recurrent laryngeal nerves
- Keywords
- Thyroid surgery, Intraoperative neuromonitoring, Recurrent Laryngeal Nerve Injuries
- Medical subject headings
- Thyroid Diseases, Recurrent Laryngeal Nerve Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromonitoring of the recurrent laryngeal nervesDevice
The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
| Study group | Role | What they receive |
|---|---|---|
| i-IONM | Active comparator | In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy. Receives: Device: Neuromonitoring of the recurrent laryngeal nerves |
| NerveTrend | Experimental | In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone). Receives: Device: Neuromonitoring of the recurrent laryngeal nerves |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of recurrent laryngeal nerve injury (%) assessed by direct laryngoscopy
The primary outcome measure is prevalence of recurrent laryngeal nerve (RLN) injury (%) on postoperative day 1 assessed by direct laryngoscopy.
Measured: Postoperative day 1
Secondary outcomes (3)
Positive predictive value (%) of introperative neuromonitoring of recurrent laryngeal nerves in prognostication of postoperative glottis function assessed by direct laryngoscopy
Positive predictive value (%) of introperative neuromonitoring of recurrent laryngeal nerves in prognostication of postoperative glottis function assessed by direct laryngoscopy stratified to the respective mode of application (i-IONM vs. NerveTrend).
Measured: Postoperative day 1
Negative predictive value (%) of introperative neuromonitoring of recurrent laryngeal nerves in prognostication of postoperative glottis function assessed by direct laryngoscopy
Negative predictive value (%) of introperative neuromonitoring of recurrent laryngeal nerves in prognostication of postoperative glottis function assessed by direct laryngoscopy stratified to the respective mode of application (i-IONM vs. NerveTrend).
Measured: Postoperative day 1
Prevalence of permanent recurrent laryngeal nerve injury (%) assessed by direct laryngoscopy
Prevalence of permanent recurrent laryngeal nerve (RLN) injury (%) at 6 months postoperatively assessed by direct laryngoscopy stratified to the respective mode of application (i-IONM vs. NerveTrend).
Measured: At 6 months postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2021
- Study start1 Apr 2021
- Primary completion31 Dec 2022 (estimated)
- Study completion31 Mar 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Thyroid DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each). Patients referred to the Department of Endocrine Surgery, Third Department of General Surgery, Jagiellonian University Medical College in Krakow, for first-time thyroid surgery from April 1, 2021 onwards will be registered. Eligible patients with either benign or malignant thyroid disease will be assessed for the study. The study will be approved by the Institutional Review Board (Bioethics Committee of the Jagiellonian University).
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 264 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Marcin Barczynski
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Marcin Barczynski, Jagiellonian University
- Investigators
- Marcin Barczynski, Principal investigator, Department of Endocrine Surgery, Jagiellonian University College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04794257
- Sponsor's protocol ID
- ERP-2020-12499
- Status last verified
- May 2021
- First submitted
- 7 Mar 2021
- Last updated
- 4 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Randolph GW, Dralle H; International Intraoperative Monitoring Study Group; Abdullah H, Barczynski M, Bellantone R, Brauckhoff M, Carnaille B, Cherenko S, Chiang FY, Dionigi G, Finck C, Hartl D, Kamani D, Lorenz K, Miccolli P, Mihai R, Miyauchi A, Orloff L, Perrier N, Poveda MD, Romanchishen A, Serpell J, Sitges-Serra A, Sloan T, Van Slycke S, Snyder S, Takami H, Volpi E, Woodson G. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope. 2011 Jan;121 Suppl 1:S1-16. doi: 10.1002/lary.21119.
PubMed 21181860Schneider R, Randolph GW, Dionigi G, Wu CW, Barczynski M, Chiang FY, Al-Quaryshi Z, Angelos P, Brauckhoff K, Cernea CR, Chaplin J, Cheetham J, Davies L, Goretzki PE, Hartl D, Kamani D, Kandil E, Kyriazidis N, Liddy W, Orloff L, Scharpf J, Serpell J, Shin JJ, Sinclair CF, Singer MC, Snyder SK, Tolley NS, Van Slycke S, Volpi E, Witterick I, Wong RJ, Woodson G, Zafereo M, Dralle H. International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope. 2018 Oct;128 Suppl 3:S1-S17. doi: 10.1002/lary.27359. Epub 2018 Oct 5.
PubMed 30289983Barczynski M, Konturek A, Stopa M, Honowska A, Nowak W. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg. 2012 Jun;36(6):1340-7. doi: 10.1007/s00268-012-1547-7.
PubMed 22402975
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Validation of NerveTrend vs. Conventional i-IONM Mode of NIM Vital in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.
- ClinicalTrials.gov ID
- NCT04794257
- Acronym / sponsor ID
- ERP-2020-12499
- Keywords
- Thyroid surgery, Intraoperative neuromonitoring, Recurrent Laryngeal Nerve Injuries
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 264 participants (estimated)
- Lead sponsor
- Marcin BarczynskiUniversity, hospital or other
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 31 Mar 2023 (estimated)
- First posted
- 12 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare two distinct modes of NIM Vital application in thyroid surgery: i-IONM vs. NerveTrend mode with respect to prevalence of early postoperative RLN injury.
The hypothesis explored in this study is that NerveTrend mode may be more accurate than conventional i-IONM mode in intraoperative identification of impending neural injury and in prognostication of postoperative glottis function in monitored bilateral thyroid surgery. Hence, NerveTrend mode may be considered a bridge between i-IONM and c-IONM modes, and particularly in health care environments with limited financial resources it can be considered a substantial step forward representing a modern alternative to the c-IONM technique and providing benefits over conventional i-IONM mode.
A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each).
The primary outcome measure is prevalence of recurrent laryngeal nerve (RLN) injury (%) on postoperative day 1 assessed by direct laryngoscopy.
Detailed description
Over the past two decades, intraoperative neural monitoring (IONM) has evolved into a mature risk minimization tool. Meta-analyses of studies, most of which were limited by poor study designs and the sole use of intermittent nerve stimulation, failed to clearly demonstrate superiority of intermittent IONM (i-IONM) over anatomic visual recurrent laryngeal nerve (RLN) dissection in the absence of IONM. However, a substantial number of systematic reviews of i-IONM in thyroidectomy have conflicting results, but their mean methodological quality is critically low. Sanabria et al suggested that design of a systematic review should comply with methodological standards and recommendations to offer relevant and practical information for decision making. In particular, with the advent of continuous IONM (c-IONM), intraoperative nerve electromyographic tracings, registered almost in real time during the operation, accurately predict postoperative vocal fold function when International Neural Monitoring Study Group (INMSG) quality standards are adhered to. Despite promising data on benefits of c-IONM is still remains rarely utilized worldwide in thyroid surgery. C-IONM aids in avoiding permanent traction-related nerve injury by urging surgeons to reverse harmful surgical maneuvers. C-IONM also forms an integral part in the surgical concept of staged thyroidectomy. Delaying completion surgery on the other side until nerve function has recovered practically abolishes the risk of bilateral vocal fold palsy. C-IONM has greatly furthered our understanding of functional RLN injury, enabling conception of effective risk minimization strategies tailored to the individual patient. As recently reported by Schneider at al c-IONM is superior to i-IONM in preventing vocal cord palsy. Based on nerves at risk (5208 versus 5024 nerves), c-IONM had in this study a 1.7-fold lower early postoperative vocal cord palsy rate than i-IONM (1.5 versus 2.5 %). This translated into a 30-fold lower permanent vocal cord palsy rate (0.02 versus 0.6 %). Early postoperative vocal cord palsies were 17.9-fold less likely to become permanent with c-IONM than i-IONM.
On the other hand, a brand new NIM Vital equipment allows now for using i-IONM in quasi continuous mode which is termed NerveTrend mode. This concept is a natural evolution of i-IONM towards c-IONM mode but is operator dependent and not automatic as in c-IONM mode. Hence, careful clinical validation of NerveTrend mode is needed in order to identify its clinical pertinence with respect to preventing neural damage compared to the standard of i-IONM mode in thyroid surgery. A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each).
Patients who will sign the informed consent will be randomized to two groups: i-IONM vs. NerveTrend application during planned total thyroidectomy.
The standardized approach to IONM will be used as outlined by the guidelines of the International Neural Monitoring Study Group in Thyroid and Parathyroid Surgery.
All the operations will be performed under general anesthesia by two experienced endocrine surgeons (MB, AK) with annual volume of thyroid surgery > 300 cases, each. The anesthesia protocol is: intravenous midazolam premedication, induction with fentanyl, thiopental and suxamethonium, endotracheal intubation and sevoflurane maintenance. No other muscle relaxants are used during surgery. A standard cervicotomy is used in all the patients. Visual identification of RLN low in the neck (below the crossing with the inferior thyroid artery) will facilitated by the use of the IONM system employing the nerve mapping technique. Once the nerve iss visually identified, repeated stimulations with the IONM monopolar probe served to trace the nerve path in the operative field and test its functional integrity during dissection. In each patient, RLN will be exposed and the branches of the superior and inferior thyroid arteries will be divided close to the thyroid capsule.
NIM Vital (Medtronic, Jacksonville, US) will be used. The NIM Vital system operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid ("laryngeal twitch"). In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
LOS is defined as absence of EMG signal following stimulation of the ipsilateral vagus nerve, EMG signal amplitude below 100 μV following stimulation with 1-2 mA current in dry field, lack of palpable "laryngeal twitch" or visible laryngeal movement following stimulation of the ipsilateral vagus nerve. To differentiate between true and false LOS, the INMSG-proposed problem-solving algorithm will be employed intraoperatively. In cases intraoperatively recognized as true LOS, the neuromapping technique is used to determine the character of nerve damage (segmental- type I, global - type II), and the localization of the injury site.
IONM assessment is based on the definition by Chan and Lo. The percentage of RLN dysfunctions is calculated per the number of RLNs at risk and not per the number of patients. Loss of signal after vagal stimulation following thyroid lobe resection (V2) is classified as a positive test result prognosticating ipsilateral vocal cord paresis. The test is interpreted as true positive (TP) when laryngoscopy confirmed ipsilateral vocal cord paresis, and false positive (FP) when the mobility of the ipsilateral vocal fold is normal. Preserved normal signal following vagal stimulation after thyroid lobe resection (V2) is classified as a negative result that prognosticated normal postoperative mobility of the ipsilateral vocal fold. The test is interpreted as true negative (TN) when laryngoscopy demonstrated postoperative normal mobility of the ipsilateral vocal fold and as false negative (FN) when ipsilateral vocal fold paresis is seen postoperatively.
Power calculation for the study: The sample size is estimated based on the principle of detecting a 5% difference in the prevalence of early RLN injury (6% for i-IONM vs. 1% for NerveTrend) with a 80% probability at p < 0.05. Assuming a 20% drop out rate a group of 528 nerves at risk (assessed in 264 patients undergoing bilateral thyroid surgery) should be enough to test if clinically pertinent differences exist between i-IONM vs. NerveTrend modes (n = 264 nerves at risk which is equal to 132 patients in each respective group undergoing bilateral thyroid surgery). The resultant data will be statistically processed using the statistical software MedCalc (version 19, MedCalc Software, Belgium). Assessment of the changeability of the investigated parameters will be presented by arithmetic means, median values, standard deviations (SD), minimum and maximum values (min - max), 95% confidence interval (95% CI) and percentage of prevalence (%). An inter-group comparison of particular properties will be done by means of the Chi-2 test (non-parametric variables) and by the univariate analysis of variance ANOVA (parametric variables). To assess the diagnostic accuracy of intraoperative neuromonitoring, the Receiver Operating Characteristics (ROC) curves will be analyzed and the Area Under Curve (AUC) values will be compared based on the non-parametric method of DeLong et al.
Thus, the predictive values of the positive and negative results will be calculated and the most optimal predictive criterion will be identified for i-IONM vs NerveTrend, separately. The incidence of nerve events will be calculated based on the number of nerves at risk. The significance level is accepted at p < 0.05.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each). Patients referred to the Department of Endocrine Surgery, Third Department of General Surgery, Jagiellonian University Medical College in Krakow, for first-time thyroid surgery from April 1, 2021 onwards will be registered. Eligible patients with either benign or malignant thyroid disease will be assessed for the study. The study will be approved by the Institutional Review Board (Bioethics Committee of the Jagiellonian University).
| Arm | Type | Receives |
|---|---|---|
| i-IONM | Active comparator | Device: Neuromonitoring of the recurrent laryngeal nervesIn operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy. |
| NerveTrend | Experimental | Device: Neuromonitoring of the recurrent laryngeal nervesIn operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- planned, first-time, bilateral thyroid surgery.
Key exclusion criteria (8 listed)
- planned unilateral thyroid surgery,
- previous thyroid surgery,
- pregnancy
- lactation
- age < 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuromonitoring of the recurrent laryngeal nervesThe NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid. | Device | NerveTrend, i-IONM |
Primary outcome
Prevalence of recurrent laryngeal nerve injury (%) assessed by direct laryngoscopy
Time frame: Postoperative day 1
The primary outcome measure is prevalence of recurrent laryngeal nerve (RLN) injury (%) on postoperative day 1 assessed by direct laryngoscopy.
3 secondary outcomes
Positive predictive value (%) of introperative neuromonitoring of recurrent laryngeal nerves in prognostication of postoperative glottis function assessed by direct laryngoscopy
Time frame: Postoperative day 1
Negative predictive value (%) of introperative neuromonitoring of recurrent laryngeal nerves in prognostication of postoperative glottis function assessed by direct laryngoscopy
Time frame: Postoperative day 1
Prevalence of permanent recurrent laryngeal nerve injury (%) assessed by direct laryngoscopy
Time frame: At 6 months postoperatively
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2021.
- Background: PubMed 21181860Randolph GW, Dralle H; International Intraoperative Monitoring Study Group; Abdullah H, Barczynski M, Bellantone R, Brauckhoff M, Carnaille B, Cherenko S, Chiang FY, Dionigi G, Finck C, Hartl D, Kamani D, Lorenz K, Miccolli P, Mihai R, Miyauchi A, Orloff L, Perrier N, Poveda MD, Romanchishen A, Serpell J, Sitges-Serra A, Sloan T, Van Slycke S, Snyder S, Takami H, Volpi E, Woodson G. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope. 2011 Jan;121 Suppl 1:S1-16. doi: 10.1002/lary.21119.
- Background: PubMed 30289983Schneider R, Randolph GW, Dionigi G, Wu CW, Barczynski M, Chiang FY, Al-Quaryshi Z, Angelos P, Brauckhoff K, Cernea CR, Chaplin J, Cheetham J, Davies L, Goretzki PE, Hartl D, Kamani D, Kandil E, Kyriazidis N, Liddy W, Orloff L, Scharpf J, Serpell J, Shin JJ, Sinclair CF, Singer MC, Snyder SK, Tolley NS, Van Slycke S, Volpi E, Witterick I, Wong RJ, Woodson G, Zafereo M, Dralle H. International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope. 2018 Oct;128 Suppl 3:S1-S17. doi: 10.1002/lary.27359. Epub 2018 Oct 5.
- Results publication: PubMed 22402975Barczynski M, Konturek A, Stopa M, Honowska A, Nowak W. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg. 2012 Jun;36(6):1340-7. doi: 10.1007/s00268-012-1547-7.
- Individual participant dataSharing planned: No
Related trials for Thyroid Diseases
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marcin Barczynski principal investigator
Department of Endocrine Surgery, Jagiellonian University College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuromonitoring of the recurrent laryngeal nerves in people with Thyroid Diseases and Surgery, run by Marcin Barczynski at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Marcin Barczynski, MD, PhD (+48602375939, marbar@mp.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of recurrent laryngeal nerve injury (%) assessed by direct laryngoscopy (time frame: Postoperative day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04794257, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2021.